Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine

ABSTRACT Our goal is to develop a pediatric combination vaccine to protect the vulnerable infant population against human immunodeficiency virus type 1 (HIV-1) and tuberculosis (TB) infections. The vaccine consists of an auxotroph Mycobacterium tuberculosis strain that coexpresses HIV antigens. Utilizing an infant rhesus macaque model, we have previously shown that this attenuated M. tuberculosis (AMtb)-simian immunodeficiency virus (SIV) vaccine is immunogenic, and although the vaccine did not prevent oral SIV infection, a subset of vaccinated animals was able to partially control virus replication. However, unexpectedly, vaccinated infants required fewer SIV exposures to become infected compared to naive controls. Considering that the current TB vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), can induce potent innate immune responses and confer pathogen-unspecific trained immunity, we hypothesized that an imbalance between enhanced myeloid cell function and immune activation might have influenced the outcome of oral SIV challenge in AMtb-SIV-vaccinated infants. To address this question, we used archived samples from unchallenged animals from our previous AMtb-SIV vaccine studies and vaccinated additional infant macaques with BCG or AMtb only. Our results show that vaccinated infants, regardless of vaccine strain or regimen, had enhanced myeloid cell responses. However, CD4+ T cells were concurrently activated, and the persistence of these activated target cells in oral and/or gastrointestinal tissues may have facilitated oral SIV infection. Immune activation was more pronounced in BCG-vaccinated infant macaques than in AMtb-vaccinated infant macaques, indicating a role for vaccine attenuation. These findings underline the importance of understanding the interplay of vaccine-induced immunity and immune activation and its effect on HIV acquisition risk and outcome in infants.

[1]  M. Hudgens,et al.  Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques , 2016, Journal of Virology.

[2]  G. Learn,et al.  Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques , 2016, Proceedings of the National Academy of Sciences.

[3]  M. Tameris,et al.  T-cell activation is an immune correlate of risk in BCG vaccinated infants , 2016, Nature Communications.

[4]  J. Berzofsky,et al.  Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum , 2016, Journal of acquired immune deficiency syndromes.

[5]  P. Karakousis,et al.  TLR2-Modulating Lipoproteins of the Mycobacterium tuberculosis Complex Enhance the HIV Infectivity of CD4+ T Cells , 2016, PloS one.

[6]  L. Joosten,et al.  Immune defence against Candida fungal infections , 2015, Nature Reviews Immunology.

[7]  G. E. Etokebe,et al.  Genetic Polymorphisms in the Toll‐like Receptor 10, Interleukin (IL)17A and IL17F Genes Differently Affect the Risk for Tuberculosis in Croatian Population , 2015, Scandinavian journal of immunology.

[8]  M. Netea,et al.  Innate immune memory: a paradigm shift in understanding host defense , 2015, Nature Immunology.

[9]  M. Hudgens,et al.  The interplay between immune maturation, age, chronic viral infection and environment , 2015, Immunity & Ageing.

[10]  Shi-sheng Feng,et al.  Association between toll-like receptors 9 (TLR9) gene polymorphism and risk of pulmonary tuberculosis: meta-analysis , 2015, BMC Pulmonary Medicine.

[11]  J. Baeten,et al.  Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples. , 2015, The Journal of infectious diseases.

[12]  P. Aaby,et al.  Changes in BCG Vaccination Policy Should Consider the Effect on Child Health. , 2015, The Journal of infectious diseases.

[13]  Jeffrey N. Martin,et al.  Gut epithelial barrier and systemic inflammation during chronic HIV infection , 2015, AIDS.

[14]  N. Sardesai,et al.  Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques , 2014, Proceedings of the National Academy of Sciences.

[15]  R. Xavier,et al.  BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. , 2014, Clinical immunology.

[16]  N. Frahm,et al.  Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study , 2014, PloS one.

[17]  M. Netea,et al.  Heterologous Immunological Effects of Early BCG Vaccination in Low-Birth-Weight Infants in Guinea-Bissau: A Randomized-controlled Trial , 2014, The Journal of infectious diseases.

[18]  Christopher J. Miller,et al.  Infection with Host-Range Mutant Adenovirus 5 Suppresses Innate Immunity and Induces Systemic CD4+ T Cell Activation in Rhesus Macaques , 2014, PloS one.

[19]  Bing Chen,et al.  Specialized Transduction Designed for Precise High-Throughput Unmarked Deletions in Mycobacterium tuberculosis , 2014, mBio.

[20]  B. Eisele,et al.  The BCG replacement vaccine VPM1002: from drawing board to clinical trial , 2014, Expert review of vaccines.

[21]  A. Gabelle,et al.  Systemic Delivery of siRNA Down Regulates Brain Prion Protein and Ameliorates Neuropathology in Prion Disorder , 2014, PloS one.

[22]  M. Woda,et al.  Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to heterologous infant vaccines , 2014, Trials in vaccinology.

[23]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[24]  R. Xavier,et al.  Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity , 2013, Journal of Innate Immunity.

[25]  B. Gicquel,et al.  Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. , 2013, Vaccine.

[26]  Peter Aaby,et al.  A small jab - a big effect: nonspecific immunomodulation by vaccines. , 2013, Trends in immunology.

[27]  W. Jacobs,et al.  Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice , 2013, PloS one.

[28]  J. Brenchley,et al.  Rate of AIDS Progression Is Associated with Gastrointestinal Dysfunction in Simian Immunodeficiency Virus–Infected Pigtail Macaques , 2013, The Journal of Immunology.

[29]  Octavio A. Quiñones,et al.  Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. , 2013, The Journal of infectious diseases.

[30]  W. Jacobs,et al.  Robust Immunity to an Auxotrophic Mycobacterium bovis BCG-VLP Prime-Boost HIV Vaccine Candidate in a Nonhuman Primate Model , 2013, Journal of Virology.

[31]  M. Altfeld,et al.  Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. , 2012, The Journal of infectious diseases.

[32]  R. Xavier,et al.  Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes , 2012, Proceedings of the National Academy of Sciences.

[33]  R. Siliciano,et al.  Mycobacterium tuberculosis Complex Enhances Susceptibility of CD4 T Cells to HIV through a TLR2-Mediated Pathway , 2012, PloS one.

[34]  K. Überla,et al.  Risk of Immunodeficiency Virus Infection May Increase with Vaccine-Induced Immune Response , 2012, Journal of Virology.

[35]  P. Tiwari,et al.  Genetic polymorphisms of CCL2, CCL5, CCR2 and CCR5 genes in Sahariya tribe of North Central India: an association study with pulmonary tuberculosis. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[36]  Ofer Levy,et al.  Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. , 2012, The Journal of allergy and clinical immunology.

[37]  W. Jacobs,et al.  A Recombinant Attenuated Mycobacterium tuberculosis Vaccine Strain Is Safe in Immunosuppressed Simian Immunodeficiency Virus-Infected Infant Macaques , 2012, Clinical and Vaccine Immunology.

[38]  W. Jacobs,et al.  Priming with a Recombinant Pantothenate Auxotroph of Mycobacterium bovis BCG and Boosting with MVA Elicits HIV-1 Gag Specific CD8+ T Cells , 2012, PloS one.

[39]  D. Montefiori,et al.  Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Recombinant Priming and Envelope Protein Boosting Elicits Localized, Mucosal IgA Immunity in Rhesus Macaques Correlated with Delayed Acquisition following a Repeated Low-Dose Rectal SIVmac251 Challenge , 2012, Journal of Virology.

[40]  J. Sadoff,et al.  Optimizing HIV‐1‐specific CD8+ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors , 2011, European journal of immunology.

[41]  Christopher J. Miller,et al.  TRIM5α Does Not Affect Simian Immunodeficiency Virus SIVmac251 Replication in Vaccinated or Unvaccinated Indian Rhesus Macaques following Intrarectal Challenge Exposure , 2011, Journal of Virology.

[42]  M. Hudgens,et al.  Enhanced Control of Pathogenic Simian Immunodeficiency Virus SIVmac239 Replication in Macaques Immunized with an Interleukin-12 Plasmid and a DNA Prime-Viral Vector Boost Vaccine Regimen , 2011, Journal of Virology.

[43]  K. Mansfield,et al.  Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. , 2011, Vaccine.

[44]  P. Earl,et al.  Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. , 2011, Vaccine.

[45]  J. Gatell,et al.  Newborn Mice Vaccination with BCG.HIVA222 + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes , 2011, Clinical & developmental immunology.

[46]  Ruchi M. Newman,et al.  TRIM5 Suppresses Cross-Species Transmission of a Primate Immunodeficiency Virus and Selects for Emergence of Resistant Variants in the New Species , 2010, PLoS biology.

[47]  S. Pittaluga,et al.  Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections , 2010, PLoS pathogens.

[48]  D. Goldstein,et al.  Contributions of Mamu-A*01 Status and TRIM5 Allele Expression, But Not CCL3L Copy Number Variation, to the Control of SIVmac251 Replication in Indian-Origin Rhesus Monkeys , 2010, PLoS genetics.

[49]  S. Soneji,et al.  Safety and Immunogenicity of Novel Recombinant BCG and Modified Vaccinia Virus Ankara Vaccines in Neonate Rhesus Macaques , 2010, Journal of Virology.

[50]  W. Jacobs,et al.  Balancing safety and immunogenicity in live-attenuated mycobacterial vaccines for use in humans at risk for HIV: response to misleading comments in Ranganathan et al. "recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env , 2010, Vaccine.

[51]  E. Halpern,et al.  Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage , 2010, Journal of leukocyte biology.

[52]  G. Jarvis,et al.  Neisseria gonorrhoeae Enhances HIV-1 Infection of Primary Resting CD4+ T Cells through TLR2 Activation , 2010, The Journal of Immunology.

[53]  P. Moss,et al.  Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin α4β7 , 2010, AIDS.

[54]  W. Jacobs,et al.  Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. , 2009, Vaccine.

[55]  G. Dickson,et al.  Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[56]  J. Gatell,et al.  P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes , 2009, Retrovirology.

[57]  S. McCormack,et al.  Faculty Opinions recommendation of Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. , 2009 .

[58]  J. Mascola,et al.  Systemic and Mucosal T-Lymphocyte Activation Induced by Recombinant Adenovirus Vaccines in Rhesus Monkeys , 2009, Journal of Virology.

[59]  B. Haynes,et al.  Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. , 2009, Vaccine.

[60]  S. Rowland-Jones,et al.  Lessons from the failure of the adenovector HIV vaccine , 2009, F1000 biology reports.

[61]  B. Haynes,et al.  Recombinant Mycobacterium bovis BCG Prime-Recombinant Adenovirus Boost Vaccination in Rhesus Monkeys Elicits Robust Polyfunctional Simian Immunodeficiency Virus-Specific T-Cell Responses , 2009, Journal of Virology.

[62]  B. Eley,et al.  BCG vaccination in South African HIV-exposed infants--risks and benefits. , 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[63]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[64]  R. Sékaly.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? , 2008, The Journal of experimental medicine.

[65]  T. Lancet.  STEP study: disappointing, but not a failure , 2007, The Lancet.

[66]  A. Hughes,et al.  CD8+ T Cells from SIV Elite Controller Macaques Recognize Mamu-B*08-Bound Epitopes and Select for Widespread Viral Variation , 2007, PloS one.

[67]  M. Carrington,et al.  The Major Histocompatibility Complex Class II Alleles Mamu-DRB1*1003 and -DRB1*0306 Are Enriched in a Cohort of Simian Immunodeficiency Virus-Infected Rhesus Macaque Elite Controllers , 2007, Journal of Virology.

[68]  M. Tremblay,et al.  TLR2 Signaling Renders Quiescent Naive and Memory CD4+ T Cells More Susceptible to Productive Infection with X4 and R5 HIV-Type 11 , 2007, The Journal of Immunology.

[69]  D. Watkins,et al.  Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes , 2007, Immunogenetics.

[70]  J. Gatell,et al.  Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding , 2007, Journal of Virology.

[71]  M. Carrington,et al.  Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.

[72]  R. Gie,et al.  The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. , 2007, Vaccine.

[73]  O. Levy,et al.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. , 2006, Blood.

[74]  A. Wurcel,et al.  CD16+ Monocyte-Derived Macrophages Activate Resting T Cells for HIV Infection by Producing CCR3 and CCR4 Ligands1 , 2006, The Journal of Immunology.

[75]  M. Carrington,et al.  The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2006, Journal of Virology.

[76]  C. Dye,et al.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.

[77]  B. Haynes,et al.  Generation of CD8+ T-Cell Responses by a Recombinant Nonpathogenic Mycobacterium smegmatis Vaccine Vector Expressing Human Immunodeficiency Virus Type 1 Env , 2006, Journal of Virology.

[78]  Bjoern Peters,et al.  The High Frequency Indian Rhesus Macaque MHC Class I Molecule, Mamu-B*01, Does Not Appear to Be Involved in CD8+ T Lymphocyte Responses to SIVmac2391 , 2005, The Journal of Immunology.

[79]  M. Kanekiyo,et al.  Priming-Boosting Vaccination with Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and a Nonreplicating Vaccinia Virus Recombinant Leads to Long-Lasting and Effective Immunity , 2005, Journal of Virology.

[80]  Danielle Harvey,et al.  Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV , 2005, Journal of acquired immune deficiency syndromes.

[81]  S. Zolla-Pazner,et al.  Vaccination of Rhesus Macaques with Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Env V3 Elicits Neutralizing Antibody-Mediated Protection against Simian-Human Immunodeficiency Virus with a Homologous but Not a Heterologous V3 Motif , 2005, Journal of Virology.

[82]  R. Singh,et al.  The Clinical Benefits of Tenofovir for Simian Immunodeficiency Virus–Infected Macaques Are Larger Than Predicted by its Effects on Standard Viral and Immunologic Parameters , 2004, Journal of acquired immune deficiency syndromes.

[83]  Todd M. Allen,et al.  Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte Responses , 2003, Journal of Virology.

[84]  Todd M. Allen,et al.  Expression of the Major Histocompatibility Complex Class I Molecule Mamu-A*01 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2003, Journal of Virology.

[85]  M. Krawczak,et al.  MHC Class I Alleles Influence Set-Point Viral Load and Survival Time in Simian Immunodeficiency Virus-Infected Rhesus Monkeys1 , 2002, The Journal of Immunology.

[86]  Todd M. Allen,et al.  Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. , 2002, Virology.

[87]  M. Newport,et al.  Influence of Mycobacterium bovis Bacillus Calmette-Guérin on Antibody and Cytokine Responses to Human Neonatal Vaccination1 , 2002, The Journal of Immunology.

[88]  D. Watkins,et al.  Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. , 1999, Immunology letters.

[89]  Andrew N. Rowan.  Guide for the Care and Use of Laboratory Animals , 1996 .

[90]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[91]  F. Mosteller,et al.  Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature , 1994 .

[92]  V. Diwan,et al.  Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. , 1993, International journal of epidemiology.

[93]  N. Letvin,et al.  Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. , 1993, Journal of immunology.

[94]  R. Young,et al.  Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines , 1991, Nature.

[95]  O. Levy,et al.  Ready to benefit from training: heterologous effects of early life immunization. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[96]  M. Netea,et al.  Trained immunity: consequences for the heterologous effects of BCG vaccination. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[97]  W. Jacobs,et al.  A neonatal oral Mycobacterium tuberculosis-SIV prime / intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques. , 2013, Trials in vaccinology.

[98]  Paul,et al.  University of Birmingham Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7 , 2011 .

[99]  S. Gichuhi.  Partners In Prevention Hsv/hiv Transmission Study Team , 2010 .